TuisAMRN • NASDAQ
add
Amarin Corporation plc
Vorige sluiting
$0,78
Dagwisseling
$0,78 - $0,79
Jaarwisseling
$0,63 - $1,37
Markkapitalisasie
326,38 m USD
Gemiddelde volume
1,46 m
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Inkomste | 56,52 m | -34,26% |
Bedryfskoste | 45,49 m | -30,31% |
Netto inkomste | -9,95 m | 39,53% |
Netto winsgrens | -17,61 | 8,04% |
Wins per aandeel | -0,01 | -150,00% |
EBITDA | -12,82 m | -196,65% |
Effektiewe belastingkoers | -15,00% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 308,18 m | 1,25% |
Totale bates | 790,01 m | -8,16% |
Totale aanspreeklikheid | 244,08 m | -11,37% |
Totale ekwiteit | 545,94 m | — |
Uitstaande aandele | 410,87 m | — |
Prys om te bespreek | 0,59 | — |
Opbrengs op bates | -4,19% | — |
Opbrengs op kapitaal | -6,07% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Mrt. 2024info | J/J-verandering |
|---|---|---|
Netto inkomste | -9,95 m | 39,53% |
Kontant van bedrywe | -12,60 m | -79,81% |
Kontant van beleggings | 28,72 m | 246,45% |
Kontant van finansiering | -1,43 m | -491,76% |
Netto kontantverandering | 14,69 m | 155,96% |
Beskikbare kontantvloei | -12,69 m | 6,80% |
Meer oor
Amarin Corporation is an Irish-American biopharmaceutical company founded in 1993 and headquartered in Dublin, Ireland and Bridgewater, New Jersey. The company develops and markets medicines for the treatment of cardiovascular disease. It has developed the drug Vascepa, a prescription grade omega-3 fatty acid.
In July 2012, their lead-candidate drug named Vascepa received FDA-approval, competing against GlaxoSmithKline's Lovaza. Wikipedia
Gestig
01 Mrt. 1989
Hoofkwartier
Webwerf
Werknemers
275
